High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome
- PMID: 22089392
- DOI: 10.1007/s10165-011-0556-y
High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome
Abstract
Recently, it was reported that remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome could be complicated with solid tumors. In a retrospective, multicenter study between October, 2003 and September, 2010, we investigated the characteristics of patients with paraneoplastic RS3PE syndrome who fulfilled following criteria: (1) bilateral pitting edema of hands or feet or both, (2) sudden onset of polyarthritis, and (3) age >50 years, (4) seronegativity for rheumatoid factor (RF). A total of 33 cases fulfilled the above criteria. Eight patients (seven men and one woman) developed cancer within 2 years of RS3PE syndrome onset. There was no significant difference between the neoplastic and nonneoplastic groups in the proportions of patients with fever, symmetrical polyarthritis, pitting edema, and good response to corticosteroids. Serum matrix metalloproteinase 3 (MMP-3) level (median 437.3 ng/ml) in the paraneoplastic RS3PE patients was significantly higher than that in patients without neoplasia (median 114.7 ng/ml) (p < 0.05). We found that high serum MMP-3 is characteristic of patients with paraneoplastic RS3PE syndrome.
Similar articles
-
Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis?J Rheumatol. 1999 Jan;26(1):115-20. J Rheumatol. 1999. PMID: 9918251
-
Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema.Clin Exp Rheumatol. 1999 Nov-Dec;17(6):741-4. Clin Exp Rheumatol. 1999. PMID: 10609077 Review.
-
Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia.J Rheumatol. 2005 Sep;32(9):1760-1. J Rheumatol. 2005. PMID: 16142875
-
The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalán Group for the Study of RS3PE.J Rheumatol. 1997 Feb;24(2):333-6. J Rheumatol. 1997. PMID: 9034993
-
Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis?Semin Arthritis Rheum. 2010 Aug;40(1):89-94. doi: 10.1016/j.semarthrit.2008.11.006. Epub 2009 Feb 13. Semin Arthritis Rheum. 2010. PMID: 19217650 Review.
Cited by
-
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome Precedes the Development of Hepatocellular Carcinoma.JMA J. 2022 Jul 15;5(3):393-397. doi: 10.31662/jmaj.2022-0066. Epub 2022 Jun 17. JMA J. 2022. PMID: 35992284 Free PMC article.
-
Remitting seronegative symmetrical synovitis with pitting edema syndrome complicated with primary lung cancer.Int Cancer Conf J. 2016 Sep 26;6(1):16-21. doi: 10.1007/s13691-016-0264-8. eCollection 2017 Jan. Int Cancer Conf J. 2016. PMID: 31149462 Free PMC article.
-
Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema (RS3PE), improved following surgical resection of prostatic carcinoma: A case report.Urol Case Rep. 2020 May 3;32:101232. doi: 10.1016/j.eucr.2020.101232. eCollection 2020 Sep. Urol Case Rep. 2020. PMID: 32420039 Free PMC article.
-
Rare Case of Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome with Monoclonal Gammopathy of Undetermined Significance.Am J Case Rep. 2023 Apr 26;24:e939650. doi: 10.12659/AJCR.939650. Am J Case Rep. 2023. PMID: 37185664 Free PMC article.
-
RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer.J Immunother Precis Oncol. 2020 May 14;3(3):128-132. doi: 10.36401/JIPO-20-2. eCollection 2020 Aug. J Immunother Precis Oncol. 2020. PMID: 35663254 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous